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Abstract
Background: Insulin resistance and obesity are strongly associated with systemic cardiovascular diseases. Recent
reports have also suggested a link between insulin resistance with pulmonary arterial hypertension. The aim of this
study was to analyze pulmonary vascular function in the insulin resistant obese Zucker rat.
Methods: Large and small pulmonary arteries from obese Zucker rat and their lean counterparts were mounted for
isometric tension recording. mRNA and protein expression was measured by RT-PCR or Western blot, respectively.
KV currents were recorded in isolated pulmonary artery smooth muscle cells using the patch clamp technique.
Results: Right ventricular wall thickness was similar in obese and lean Zucker rats. Lung BMPR2, KV1.5 and 5-HT2A
receptor mRNA and protein expression and KV current density were also similar in the two rat strains. In
conductance and resistance pulmonary arteries, the similar relaxant responses to acetylcholine and nitroprusside
and unchanged lung eNOS expression revealed a preserved endothelial function. However, in resistance (but not
in conductance) pulmonary arteries from obese rats a reduced response to several vasoconstrictor agents (hypoxia,
phenylephrine and 5-HT) was observed. The hyporesponsiveness to vasoconstrictors was reversed by L-NAME and
prevented by the iNOS inhibitor 1400W.
Conclusions: In contrast to rat models of type 1 diabetes or other mice models of insulin resistance, the obese
Zucker rats did not show any of the characteristic features of pulmonary hypertension but rather a reduced
vasoconstrictor response which could be prevented by inhibition of iNOS.
Background
Pulmonary arterial hypertension (PAH) is a progressive
disease of poor prognosis characterized by vasoconstric-
tion of pulmonary arteries (PA) and proliferation of pul-
monary vascular endothelial and smooth muscle cells
leading to increase vascular resistance and right heart
failure with right ventricular hypertrophy as a hallmark
[1,2]. These pathological events are influenced by
genetic predisposition as well as environmental stimuli
[1,3]. Bone Morphogenetic Protein Receptor 2 (BMPR2)
gene mutations have been described in some PAH
patients [4] and diminished expression of its encoded
protein has also been shown in both human and animal
models of PAH [5-8]. Additionally, endothelial dysfunc-
tion and increased 5-HT contractile response have been
reported in PAH [9-11]. Several studies have reported
the involvement of KV channels in controlling mem-
brane potential of pulmonary artery smooth muscle cells
(PASMC) and PA tone [12]. Moreover, it was reported
the role of KV1.5 in the development of PAH as a result
of mutation or downregulation of the channel [13,14].
Obesity and insulin resistance have a worldwide
increasing prevalence. Despite the fact that insulin resis-
tance is strongly associated with systemic cardiovascular
diseases [15,16] the relationship with pulmonary vascu-
lar disease has been almost disregarded [17]. Recent
reports have suggested that insulin resistance might also
be associated with pulmonary hypertension in humans
[18-20] and in the ApoE deficient mice [21]. In rats
with type 1 diabetes, we have recently found pulmonary
endothelial dysfunction associated to increased superox-
ide production and upregulation of the NADPH oxidase
subunit p47
phox [8]. The Obese Zucker rat is a well
establish model of obesity and insulin resistance
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Nonetheless, the pulmonary vasculature remains
uncharacterized in this model. Therefore, the present
study was designed to analyze the pulmonary markers of
PAH including the pulmonary expression of key pro-
teins of the disease, KV currents, vascular reactivity of
PA, and right ventricular hypertrophy in obese Zucker
rats compared to their lean Zucker littermates.
Methods
Ethics statement
The present investigation conforms to the Guide for the
Care and Use of Laboratory Animals (National Institutes
of Health Publication No. 85-23, revised 1996), and the
procedures were approved by our institutional review
board (Comité de Experimentación Animal, Universidad
Complutense, 070208).
Animals, tissues and reagents
On the day of the experiment, male obese Zucker rats
(fa/fa) and their littermates, lean Zucker rats (fa/-) (17-
18 weeks old) were weighed and sacrificed by cervical
dislocation and exsanguination. Pulmonary arteries (PA)
were dissected to obtain conductance and resistance
intrapulmonary arteries. Smooth muscle cells were then
enzymatically isolated from resistance intrapulmonary
arteries [25]. Blood glucose was measured using a clini-
cal glucometer (OneTouch Ultra) and insulin using an
enzyme immunoassay. Hearts were excised, fixed with
formol embedded in paraffin and cut into 1 mm cross
sections, visualized in a microscope, photographed and
analyzed using imageJ (Ver 1.41, NIH, USA). All drugs
were from Sigma (Tres Cantos, Spain).
Vascular reactivity
Resistance (diameter ~0.3-0.5 mm and length ~2 mm)
and conductance (diameter ~1-1.2 mm and length ~3
mm) PA rings were mounted in Krebs solution at 37°C
gassed with a 95% O2-5% CO2 mixture in a wire myo-
graph or in organ chambers respectively. After stretch-
ing to give an appropriate resting tension (equivalent to
30 mm Hg as previously described [25] for resistance or
0.7 g for conductance arteries) each vessel was exposed
to different vasoconstrictor agents to test the vascular
response. The contractile responses were performed by
cumulative addition and expressed as a percentage of
the response to 80 mM KCl. The endothelial function
was estimated by the analysis of the relaxant response
to cumulative addition of acetylcholine (ACh, 10
-9-10
-
4M) after precontraction with 10
-7M phenylephrine in
conductance arteries or with a concentration of pheny-
lephrine titrated to induce a contraction 75% of the
response to KCl. Some experiments were carried out in
t h ep r e s e n c eo ft h eN O Si n h i b i t o rL - N A M E .H y p o x i a
was induced by bubbling the Krebs solution with 95%
N2-5% CO2 to achieve an oxygen concentration of 3-4%
(24 ± 1 Torr) in the chamber as described [26].
Electrophysiological studies
Membrane currents were recorded using the whole-cell
configuration of the patch clamp technique with an
Axopatch 200B and a analog to digital converter Digi-
data 1322A (Axon Instruments, Burlingame, CA, U.S.A).
pClamp version 9 software was used for data acquisition
and analysis. Cells were superfused with an external Ca
2
+-free Hepes solution (2 ml/min) and a Ca
2+-free pipette
(internal) solution containing (mmol/L): KCl 110, MgCl2
1.2, Na2ATP 5, HEPES 10, EGTA 10, pH adjusted to 7.3
with KOH. Patch pipettes (2-4 MΩ) were constructed
from borosilicate glass capillaries (GD-1, Narishige
Scientific Instruments, Tokyo, Japan) using a program-
mable horizontal puller. Currents were evoked following
the application of 200 ms depolarizing pulses from -60
mV to test potentials from -60 mV to +60 mV in 10
mV increments [27]. Hypoxia was induced by bubbling
the solution with N2 as described [26].
Protein expression
Whole lungs were homogenated under reducing condi-
tions in the presence of DTT, proteases and phospha-
tases inhibitors. Protein content was determined by Bio-
Rad DC Protein Assay Kit (Bio-Rad, Hercules, CA,
USA) and equal amounts of proteins were loaded and
subjected to electrophoresis on a SDS-PAGE (7.5-10%)
followed by a transference to a PVDF membrane (Bio-
Rad). Protein expression was quantified using primary
antibodies anti-KV1.5 (Alomone, Israel, 1:200 dilution),
anti-5HT2A (BD Biosciencies, 1:250 dilution), anti- Bone
Morphogenetic Protein Receptor 2 (BMPR2) (BD Bios-
ciencies, 1:250 dilution), anti-eNOS (BD Biosciencies,
1:2500 dilution), anti-iNOS (Santa Cruz, CA, USA, 1:500
dilution), anti-b-actin (Sigma-Aldrich, Spain, 1:5000
dilution) and horseradish peroxidase conjugated second-
ary goat anti-mouse and anti-rabbit antibodies (Santa
Cruz Biotech, CA, USA, 1:10000 dilution). Proteins were
detected using ECL-Plus Western blotting reagents
(Amersham, GE Healthcare, CT, USA) and analyzed
using Quantity One (BioRad).
Real time RT-PCR
Total RNA was isolated and purified from resistance PA
homogenates using RNeasy Mini kit (Qiagen, Hilden,
Germany) and converted into cDNA using iScript
cDNA synthesis kit (BioRad, Hemel Hempstead, UK).
Real-time PCR was performed using a Taqman system
(Roche Diagnostics, Mannheim, Germany) in the Geno-
mic Unit of Universidad Complutense de Madrid. Speci-
fic primers were designed for rat KV1.5 (sense 5’-
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Page 2 of 10GGAAGAACAAGGCAACCAGA-3’,a n t i s e n s e5 ’-AG
CTGACCTTCCGTTGACC-3’), iNOS (sense 5’-TTG
GAGTTCACCCAGTTGTG-3’,a n t i s e n s e5 ’-ACATC-
GAAGCGGCCATAG-3’), eNOS (sense 5’-GGTATTT-
GATGCTCGGGACT-3’,a n t i s e n s e5 ’-TGTGGTTACA
GATGTAGGTGAACA-3’), BMPR2 (sense 5’-CGGGC
AGGATAAATCAGGA-3’,a n t i s e n s e5 ’-CAGGAAAG-
TAAATTCGGGTGA-3’)a n db-actin (sense 5’-GCCC
TAGACTTCGAGCAAGA-3’,a n t i s e n s e5 ’-TCAGG-
CAGCTCATAGCTCTTC-3’). Data were normalized by
the expression of b-actin.
Statistical analysis
Results are expressed as mean ± s.e.m. Data for Western
blots and RT-PCR were normalized by the expression of b-
actin and expressed as a percentage of the values obtained
in the lean rats. Individual cumulative concentration-
response curves were fitted to al o g i s t i ce q u a t i o n .T h en e g a -
tive logarithm of the molar concentration that causes 50%
of the maximum response (pD2)a n dt h em a x i m u m
response (Emax) were calculated for each ring. Statistical
analysis was performed by comparing the lean and obese
Zucker groups with an unpaired Student’s t-test. Differences
were considered statistically significant when P <0 . 0 5 .
Results
Obese Zucker rats showed a final body weight ~30%
higher than their lean littermates (476 ± 29 vs 364 ± 22
g, respectively, P < 0.01, n = 20 for both groups). Non
fasting blood glucose was not significantly different (128
± 13 vs 106 ± 5 mg/dL, respectively, n = 13 and 12) but
insulin was strongly elevated (3.5 ± 0.2 vs 1.4 ± 0.2 ng/
ml, respectively, n = 7 for both groups).
Heart wall thickness and BMPR2 expression
No significant changes were found in the wall thickness
of the right ventricle (RV), the left ventricle (LV) or the
septum (S) from obese as compared with lean rats (Fig-
ure 1A). The RT-PCR analysis revealed no changes in
mRNA transcription levels of BMPR2 gene in resistance
PA (Figure 1B) and Western blots showed no significant
changes in the whole lung protein expression of BMPR2
or in its heavier precursor (pro-BMPR2) (Figure 1C).
KV currents and KV1.5 lung expression
Similar cell capacitance (17.8 ± 1.1 and 18.4 ± 0.7 pF in
obese and lean rats, respectively), as a measure of the
cell size, and similar KV current density (Figure 2A)
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Figure 1 Heart wall thickness and BMPR2 expression. (A) Left ventricular (LV), right ventricular (RV) and septal wall thickness from lean (n =
8) and obese (n = 7) Zucker rats. (B) BMPR2 mRNA expression in resistance PA of lean and obese (n = 5) analyzed by RT-PCR and normalized by
b-actin expression. (C) BMPR2 precursor (~115 KDa) and mature (~75 KDa) protein expression from obese and lean Zucker lungs (n = 8)
analyzed by Western blot and normalized by b-actin expression. Results indicate mean ± s.e.m.
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Page 3 of 10h y p o x i ai n d u c e das i m i l a ri n h i b i t i o no fK V currents in
both strains (Figure 2B). In accordance with patch-
clamp data, no changes in KV1.5 mRNA transcription in
resistance PA (Figure 2C) or whole lung protein expres-
sion (Figure 2D) were found in obese as compared to
lean rats.
Endothelial function
The endothelial function was tested in endothelium
intact PA preconstricted with phenylephrine (10
-7Mi n
conductance arteries or a concentration titrated to
induce a contraction 75% of the response to KCl in
resistance PA). Increasing concentrations of ACh
induced a similar relaxant response in obese and lean
rats in conductance arteries (Figure 3A). Resistance
arteries from obese rats required higher concentrations
of phenylephrine to achieve a tone similar to the lean
ones (5 ± 2 · 10
-6Mv s7±2·1 0
-7M, respectively). The
analysis of the concentration-response curves to ACh
shows that there were not significant changes in the
Emax values between groups in conductance (Emax 53 ±
7 vs 67 ± 9%, respectively) or resistance vessels (Emax 59
± 8 vs 66 ± 4%, respectively). Similarly, the concentra-
tion of ACh required for half-maximal relaxation in
conductance (pD2 values 6.4 ± 0.1 vs 6.2 ± 0.2, respec-
tively) or in resistance vessels (pD2 values 6.1 ± 0.2 vs
5.8 ± 0.2, respectively) was similar in both groups. In
t h ep r e s e n c eo ft h eN O Si n h i b i t o rL - N A M E ,s i m i l a r
concentrations of phenylephrine were required to induce
~75% of KCl contraction in arteries from the obese and
lean rats (3 ± 2·10
-8M and 2 ± 0.6·10
-8M, respectively)
but these concentrations were significantly lower than
those required in the absence of L-NAME. Moreover, in
the presence of this inhibitor, the relaxation to
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Figure 2 KV currents and KV1.5 expression. (A) KV current traces recorded in enzymatically isolated PASMC from lean and obese Zucker rats
with depolarizing pulses from -60 mV to +60 mV in 10 mV increments. The current-voltage relationship measured at the end of depolarizing
pulse is shown at the bottom (n = 9) and the membrane capacitance in the inset. (B) Effects of hypoxia on Kv currents in both strains (n = 7).
(C) KV1.5 mRNA expression in resistance PA from lean and obese Zucker rats analyzed by RT-PCR and normalized by b-actin expression (n = 5).
(D) KV1.5 protein expression in whole lung homogenates analyzed by Western blot and normalized by b-actin expression (n = 6). Results indicate
mean ± s.e.m.
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Page 4 of 10acetylcholine was completely abolished in both strains
(Figure 3D). In addition, no changes were found in the
response to the endothelium-independent vasodilator
sodium nitroprusside in conductance PA (Figure 3B).
Expression of eNOS mRNA in resistance PA (Figure
3C) or eNOS protein in whole lung (Figure 3D) was
also similar in both strains.
Contractile responses in conductance PA
Conductance pulmonary arteries were mounted in organ
chambers to test the contractile response to 80 mM KCl,
phenylephrine and 5-HT. No changes were found in the
responses to the vasoconstrictor agents KCl (80 mM) or
phenylephrine (10
-7M )w h e nb o t hg r o u p so fr a t sw e r e
compared (Figure 4A). A similar concentration-response
curve to 5-HT was also obtained in obese and lean rats
(Figure 4B, Emax and pD2 values are shown in Table 1).
Contractile responses in resistance PA
The contractile response to 80 mM KCl in resistance
PA showed a significant reduction in obese compared to
lean rats. Obese rats also evidenced a significant hypore-
sponsiveness to hypoxia, phenylephrine and 5-HT (Fig-
ure 5 and Table 1). We further investigated the
response to the 5-HT2 agonist a-methyl-5-HT. This
agonist also showed reduced vasoconstriction responses
in PA rings from obese rats (Table 1). Western blot ana-
lysis of whole lung homogenates revealed no changes in
the expression of 5-HT2A receptors.
Role of inducible NO synthase
To test the role of NO in the vascular hyporesponsive-
ness observed in resistance PA, the NO synthase inhibi-
tor L-NAME was added on top of the maximal response
to 5-HT. L-NAME induced a further contraction in
both arteries but it was significantly higher in the obese
rats. Therefore, no differences were found in the final
tone induced by 5-HT plus L-NAME when both groups
were compared, i.e. L-NAME restored the vascular
hyporesponsiveness to 5-HT (Figure 6A). Interestingly,
the incubation of the PA ring in the presence of the
iNOS selective inhibitor 1400W prevented the reduced
response to 5-HT observed in the PA from obese rats
and thus the responses were similar in obese and lean
rats (Figure 6B). These results suggest that iNOS might
b eas o u r c eo ft h eN Or e s p o n s i b l eo ft h ev a s c u l a r
hyporesponsiveness in the obese rats. The levels of
iNOS mRNA expression were highly variable in the
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Figure 3 Endothelial function and eNOS protein expression. (A) Concentration-response curve to acetylcholine in endothelium intact
conductance PA rings precontracted with phenylephrine 10
-7M (left) and resistance PA rings precontracted with phenyleprine to reach a 75% of
KCl contraction with or without L-NAME 10
-4 M (right) from lean and obese Zucker rats (n = 4-6). (B) Concentration-response curve to sodium
nitroprusside in conductance PA rings contracted by 5-HT (10
-4M) in the presence of L-NAME (10
-4M, n = 5). (C) eNOS mRNA levels in resistance
PA analyzed by RT-PCR and normalized by b-actin expression (n = 5) and (D) eNOS protein expression from whole lung homogenated analyzed
by Western blot and normalized by b-actin expression (n = 8). Results indicate mean ± s.e.m.
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Page 5 of 10resistance PA from both groups and even when a trend
to increased transcription of iNOS mRNA was observed,
the difference did not achieve statistical significance
(Figure 6C). However, we found a significant increase in
iNOS protein expression in resistance pulmonary
arteries from obese rats (Figure 6D).
Discussion
Epidemiological studies show that insulin resistance
appears to be more common in pulmonary
hypertension than in the general population [18]. Simi-
larly, patients with type II diabetes mellitus have signif-
icantly higher prevalence of pulmonary embolism and
pulmonary hypertension independent of coronary dis-
eases, hypertension, congestive hearth failure or smok-
ing [19]. Recent data of our group demonstrated a
marked endothelial dysfunction in PA characterized by
an increase of reactive oxygen species and by an
increased expression of p47
phox [ 8 ]a sw e l la sa
decreased BMPR2 lung expression together with exag-
gerated response of PA to 5-HT (authors unpublished
observations) in rats treated with streptozotocin as an
insulin-dependent diabetes model. Additionally, experi-
mental data demonstrated that ApoE
-/- mice on a high
f a td i e td e v e l o pP A Ha sj u d g e db ya ne l e v a t e dr i g h t
ventricular systolic pressure and augmented RV/(LV
+S) relation when compared to controls [21]. The aim
of the present study was to further investigate the rela-
tionship between insulin resistance and pulmonary
h y p e r t e n s i o n .F o rt h i sp u r p o s ew eh a v eu s e daw e l l
established genetic model of obesity and insulin resis-
tance, the obese Zucker rat, characterized by a mis-
s e n s em u t a t i o ni nt h el e p t i nr e c e p t o r[ 2 8 ]a n d
associated with several cardiovascular complications
[22,29].
Sustained elevated pulmonary pressure results in com-
pensatory right ventricular hypertrophy and, therefore,
the weight or the wall thickness of the right ventricle
can be used as an indirect index of pulmonary artery
pressure. Increased right ventricular weight compared to
the left ventricle plus the septum weight has been
described in streptozotocin-induced type 1 diabetes [30]
and in insulin resistant ApoE knockout mice [21]. How-
ever, we did not find changes in the left or right ventri-
cular wall thickness in obese Zucker rats as compared
to lean ones. Fredersdorf et al. also reported similar
heart weight in these strains [22]. Additionally, muta-
tions in the BMPR2 or the diminished expression of
BMPR2 has been described in lungs from PAH patients
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Figure 4 Vasoconstrictor responses in conductance PA.( A )
Contractile responses to KCl (80 mM, n = 5, left) and phenylephrine
(10
-7 M, n = 5, right) in conductance PA from lean and obese Zucker
rats. (B) Serotonin concentration-response curve in conductance PA
from lean and obese Zucker rats. Results indicate mean ± s.e.m.
Table 1 Parameters of the concentration-response curve to vasoconstrictor agonists in isolated conductance and
resistance PA from lean and obese Zucker rats [means ± s.e.m. (n)].
Emax(% of KCl) pD2
Lean Obese Lean Obese
Conductance PA
Phenylephrine 82.6 ± 3.2 (5) 83.7 ± 4.1(5) 8.20 ± 0.03 8.10 ± 0.09
5-HT 64.3 ± 6.5 (5) 64.4 ± 7.2(5) 5.28 ± 0.13 5.02 ± 0.11
a-methyl-5-HT 41.0 ± 9.5 (6) 30.8 ± 6.8(6) 5.32 ± 0.13 5.46 ± 0.12
Resistance PA
5-HT 69.2 ± 7.8 (6) 33.5 ± 9.1 * (6) 5.28 ± 0.10 4.86 ± 0.06 **
5-HT (1400W) 49 ± 7 (6) 58 ± 9 (6) 5.10 ± 0.13 5.24 ± 0.15
a-methyl-5-HT 33.7 ± 8.8 (4) 9.5 ± 3.6 * (4) 5.80 ± 0.11 5.58 ± 0.10
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Page 6 of 10[4] and from rats with monocrotaline- or hypoxia-
induced PAH [5-7]. Recently we also found a downregu-
lation in the lung expression of BMPR2 in streptozoto-
cin-treated rats (authors unpublished observations);
nonetheless, our RT-PCR analysis revealed no changes
in the BMPR2-mRNA levels of obese as compared to
lean rats. This was further confirmed by Western blot
analysis where the expression of neither BMPR2 nor its
heavier precursor (pro-BMPR2) were significantly
modified.
PAH has been associated with a decrease in PASMC
KV currents and with reduced expression of KV chan-
nels, mainly KV1.5, KV3.1 and KV2.1 [14]. KV1.5 mRNA
and protein expression, KV current density as well as
the inhibitory effects of hypoxia in freshly isolated
PASMC were unchanged in obese as compared to lean
rats. Additionally, PASMC from obese rats showed no
signs of hypertrophy as indicated by the capacitance
data.
Endothelial dysfunction is characterized by a dimin-
ished vasodilator response to acetylcholine due to a
reduced NO release or increase NO metabolism. Insulin
resistant states and diabetes are associated to reduced
endothelium-dependent relaxation and linked to cardio-
vascular events [31-33]. Moreover, endothelial dysfunc-
tion is a key factor in the development of retinopathy,
nephropathy and atherosclerosis in both type 1 and type
2 diabetes [34,35] and also in PAH [36]. However,
endothelial dysfunction is not consistently found in
insulin resistance. In Zucker rats, endothelial function
was impaired in the aorta and several systemic arteries
[37]. In contrast, vascular reactivity and eNOS expres-
sion or phosphorylation were unchanged in hindlimb
arteries [38]. Moreover, endothelial dysfunction was
found in penile arteries but not in coronary arteries
from obese Zucker rats in a single study [32], confirm-
ing the tissue-dependency of this effect. To our knowl-
edge pulmonary endothelial function has not been
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Figure 5 Vasoconstrictor responses in resistance PA. (A) Contractile responses of resistance PA induced by KCl (80 mM, n = 8, left), hypoxia
(n = 3, middle) and phenyleprine (10
-7 M, n = 3-4, right) in resistance PA from lean and obese Zucker rats. (B) Concentration-response curve to
5-HT (n = 6). (C) Whole lung protein expression of 5-HT2A receptor (n = 8). Results indicate mean ± s.e.m. *, ** denote P < 0.05 and P < 0.01
respectively, obese vs lean.
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Page 7 of 10analyzed in the context of insulin resistance. In the pre-
sent experiments, the ACh-relaxation curve in conduc-
tance and resistance PA and the eNOS mRNA and
protein expression were similar in obese as compared to
lean rats, indicating a preserved PA-endothelial function
in this model. However, our group has recently reported
endothelial dysfunction in PA of type 1 diabetic rats
associated to increased ROS production and increased
expression of NADPH [8] as well as hyperresponsive-
ness to 5-HT.
In contrast to all the above described similarities
between obese and lean rats, we found differences in the
constrictor response in resistance but not in conduc-
tance PA from obese rats. Resistance PA showed dimin-
ished contractile responses to hypoxia, phenylephrine,
KCl and 5-HT as compared to lean resistance PA, while
similar responses to phenylephrine, KCl or 5-HT were
found in conductance PA. In contrast, in a type 1 rat
model of diabetes decreased responses were found in
conductance but not in small PA [39]. Responses to
vasoconstrictors have been also described to be reduced
in some systemic beds from obese Zucker rats such as
the mesenteric arteries [23] but enhanced in others such
as the penile and coronary arteries [32]. Western blot
analysis revealed no changes in the whole lung expres-
sion of 5-HT2A, ruling out that downregulation of 5-
HT2A could be responsible of the reduced response to
5-HT in resistance PA.
I n d u c i b l en i t r i co x i d es y n t h a s eh a se m e r g e da sak e y
protein in insulin resistance and obesity. Moreover,
iNOS has been directly related to cardiac contractile
dysfunction [40] and in vascular complications derived
from insulin resistance [41,42]. We found that the con-
tractile response to 5-HT was increased by the non
selective NO synthase inhibitor L-NAME much more
effectively in the obese than in the lean rats, suggesting
that increased NO synthesis was responsible for the vas-
cular hyporesponsiveness in the obese rats. Furthermore,
the incubation with selective iNOS inhibitor 1400W
restored 5-HT response curve suggesting that iNOS was
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Figure 6 Role of iNOS. (A) Constrictor effect of 5-HT (10
-4M) and the additional contractile effect of L-NAME (10
-4M) on top of the response to
5-HT in resistance PA from lean (n = 7) and obese (n = 6) Zucker rats. (B) Concentration-response curves to 5-HT in the presence of 1400W (10
-
5M, n = 6) in resistance PA. (C) iNOS mRNA transcript levels in resistance PA (n = 6), (D) iNOS protein in resistance PA (n = 5 and 6, respectively).
Results indicate mean ± s.e.m. * denotes P < 0.05 (obese vs lean, unpaired t test) and # and ## denote P < 0.05 and P < 0.01, respectively (pre
vs post L-NAME paired t test).
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Page 8 of 10responsible for this exaggerated NO synthesis. Since
iNOS activity is primarily regulated at a transcriptional
level and that once expressed the enzyme produces
large amounts of NO, we investigated iNOS expression
levels. The levels of iNOS mRNA tended to be higher in
resistance PA from obese rats but differences did not
reach statistical significance due to the high variability
within our experimental samples. However the protein
iNOS expression was significantly higher in obese resis-
tance PA than in lean resistance PA. iNOS upregulation
has also been found in other tissues such as the aorta,
the visceral adipose tissue and the heart in the Zucker
obese rats and other modelso fi n s u l i nr e s i s t a n c e
[40,42,43]. There are a large number of studies showing
that increased expression of iNOS induced by lipopoly-
saccharide (LPS) is accompanied by endothelial dysfunc-
tion, as opposed to the present study. Moreover, iNOS
gene deletion or pharmacological inhibition prevents
LPS-induced endothelial dysfunction suggesting a cause-
effect relationship [44]. However, iNOS overexpression
induced by LPS is much larger (e.g. > 10 fold increase)
than in the present study. More importantly, it is perox-
ynitrite (and probably not NO itself) produced in the
reaction of iNOS-derived NO with superoxide which is
responsible for endothelial dysfunction [45]. We have
not measured superoxide or peroxynitrite in resistance
PA, but the lack of endothelial dysfunction suggests that
oxidative stress is not increased in these arteries.
Conclusions
Herein we characterized for the first time the effects of
insulin resistance in the pulmonary circulation of the
obese Zucker rats. Some studies have related insulin
resistance with PAH in humans and in other animal
models but we did not find any of the characteristic fea-
tures related with this pathology in the obese Zucker rat
at the age of 17-18 weeks. However, this rat strain
showed pulmonary vascular hyporesponsiveness in resis-
tance arteries which could be prevented by inhibition of
iNOS.
List of abbreviations
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